More Evidence to Support Shift in Standard Glaucoma Care
Six-year study results show laser treatment can preserve vision better than daily eye drops.
The trial run by chief investigator Prof Gus Gazzard, compared selective laser trabeculoplasty and glaucoma eye drops as first-line treatment in patients recently diagnosed with open-angle glaucoma or ocular hypertension.
Read the full article by the American Academy of Ophthalmology here
Evolving towards an interventional glaucoma mindset
By Gus Gazzard and Jan Beiting
Traditionally, a newly diagnosed glaucoma patient would be treated first with medical therapy. As the disease progressed or the initial intervention failed to adequately control intraocular pressure (IOP), clinicians would add more drops, selective laser trabeculoplasty (SLT), repeated SLT and still more drops, with surgery as a last resort.
In this article, Gus Gazzard and Jan Beiting discuss how this paradigm has now changed thanks to SLT and a new approach to glaucoma care.
SLT as First-Line Therapy
Glaucoma Today Cover Focus | January/February 2024
Exploring the foundation of the LIGHT study and the clinical applications of its outcomes.
Gus Gazzard, MBBChir, MA, MD, FRCOphth, joins Arsham Sheybani, MD, and Iqbal Ike K. Ahmed, MD, FRCSC, to discuss the background and results of the Laser in Glaucoma and Ocular HyperTension (LiGHT) study. Dr. Gazzard explains how to clinically apply its outcomes and comments on using selective laser trabeculoplasty (SLT) as potential first-line therapy.
The History of Eyecare Podcast
During the American Academy of Ophthalmology in October, Lumibird Medical USA hosted Dr. J. Morgan Micheletti, MD at their booth for a LIVE recording of The History of Eyecare. Dr. Micheletti got a chance to sit down with guests Dr. Mark Latina and Dr. Gus Gazzard.
Glaucoma: now and beyond
Impact review led by Professor Gazzard
Read more about the impact review ‘Glaucoma: now and beyond’ here
WGC Presentation
Watch BELKIN Vision’s World Glaucoma Conference Symposium in Rome – June 2023. Moderated by Dr. Paul Singh and joined in discussion by Prof. Gus Gazzard, Prof. Stefano Gandolfi and Dr. med Inga Kersten Gomez.
Professor Gazzard was voted in the World’s Top 10 Most Influential Ophthalmologists in April 2022.
Read more about the Power List here
You can view Professor Gazzard’s Google Scholar page here: this compiles his research, articles and h-index.
6-Year Results Support SLT for Glaucoma & Ocular Hypertension
Article in Physician’s Weekly on the impact and importance of Gazzard’s SLT research.
Professor Gus Gazzard is number 3 on the 100 Power List for The Ophthalmologist
You can read more and the full article here
Professor Gazzard’s paper was voted the 11th most impactful Glaucoma research paper ever.
From the “The American Glaucoma Society 100 Articles with Significant Impact on Clinical Glaucoma”
You can read the full list of selected articles here (PDF download)
Article featuring Professor Gus Gazzard’s work on SLT and the LiGHT Study
“Glaucoma researchers deliver verdict on SLT versus eye drops in LiGHT study”
You can read more and the full article here
Article featuring Professor Gus Gazzard’s research “How Surgery Plus Stent Slows Glaucoma Progression Better Than Surgery Alone — Five-year follow-up shows significantly less annual visual field progression with the stent”
You can read more and the full article here
Gus’s paper was selected to be European Glaucoma Society ‘Clinical Paper of the Month’ for January 2023
Professor Gazzard was interviewed by the American Society of Cataract and Refractive Surgery on the Ophthamalogy podcast on the efficacy of repeat SLT.
(only available to ASCRS members)